Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure:
Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure:
or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
C07D 267/08 - Seven-membered rings having the hetero atoms in positions 1 and 4
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
3.
METHOD OF MONITORING AND CONTROLLING THE FOAM WITHIN A VESSEL
The application relates to a method of monitoring and controlling the foam within a vessel comprising a liquid. The method comprises measuring the thickness of the foam within a vessel comprising a liquid and controlling the dosage of an antifoaming additive to be added to the liquid based on the measured thickness of the foam. The thickness of the foam is determined based on the difference between the level of a phase surface and the level of the liquid. The level of the phase surface is determined by a signal emitted towards and reflected from the phase surface. An apparatus for conducting the method, and a further method of producing biologics from cells is also disclosed.
The invention provides a compound represented by represented by the following strutural formula:
The invention provides a compound represented by represented by the following strutural formula:
or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering glofitamab in combination with gemcitabine and oxaliplatin. Further the invention related to an optimized corticosteroid prophylaxis for glofitamab resulting in lower incidence of cytokine release syndrome (CRS).
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
7.
THERAPEUTIC AGENT DELIVERY DEVICE WITH CONVERGENT LUMEN
An apparatus has a first fluid conduit, a second fluid conduit, a connector member, an first tubular member, a second tubular member, and an inner cannula. The connector member has first and second passageways in which the first and second fluid conduits are positioned, respectively. A portion of the second tubular member is positioned within the lumen of the first tubular member. A proximal portion of the inner cannula is fixedly secured within the lumen of the first tubular member. The inner cannula lumen is in fluid communication with the first and second fluid conduits via the lumen of the first tubular member and the lumen of the second tubular member. The inner cannula may be inserted into the subretinal space of a human eye to deliver a leading bleb of fluid and then deliver a therapeutic agent, without having to withdraw the inner cannula from the subretinal space between the acts of delivering the leading bleb delivering the therapeutic agent.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61M 25/06 - Body-piercing guide needles or the like
8.
PREDICTING GEOGRAPHIC ATROPHY GROWTH RATE FROM FUNDUS AUTOFLUORESCENCE IMAGES USING DEEP NEURAL NETWORKS
A method and system for evaluating geographic atrophy in a retina. A set of fundus autofluorescence (FAF) images of the retina is received. An input is generated for a machine learning system using the set of fundus autofluorescence images. A lesion area is predicted, via the machine learning system, for the geographic atrophy lesion in the retina using the set of fundus autofluorescence images. A lesion growth rate is predicted, via the machine learning system, for the geographic atrophy lesion in the retina using the input.
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G06T 3/4046 - Scaling of whole images or parts thereof, e.g. expanding or contracting using neural networks
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Disclosed are various examples for the optimal determination of dose response points for an assay. A first assay is performed and a curve is generated that is fitted to a plurality of dose responses of the first assay. It is determined whether a deviation of individual ones of the first dose responses from the curve renders the first assay invalid. A linear region and first and second endpoints of the curve are identified. A plurality of points are identified on the curve between the first and second endpoints. The points identify a corresponding plurality of second dose concentrations for a second assay.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
10.
METHODS AND COMPOSITIONS COMPRISING A SHP2 INHIBITOR AND A PD-LI BINDING ANTAGONIST
Provided herein are combination therapies comprising a SHP2 inhibitor (e.g., Compound 1) and a PD-L1 binding antagonist (e.g., atezolizumab) and methods of using such combination therapies.
Provided herein, inter alia, are methods and compositions for engineering T cells. The methods include contacting a T cell with a nucleic acid and one or more cyclic GMP-AMP synthase (cGAS)-stimulator of interferon gene (STING) pathway inhibitors. The methods provided herein are contemplated to increase cell viability, expansion and gene editing efficiency, thereby allowing an increase in the total number of engineered T cells.
The present disclosure provides animal models of wound healing and diseases associated with angiogenesis, such as age-related macular degeneration (AMD), fibrosis and cancer. The present disclosure further provides methods for identifying agents for promoting wound healing, modulating angiogenesis or treating diseases associated with angiogenesis, such as AMD and cancer.
A method, implemented by one or more computer devices, includes receiving fundus autofluorescence (FAF) image data for a retina of a subject. The FAF image data includes a first FAF image associated with a first point in time. An image input for a deep learning system is generated using the FAF image data. A predicted growth output for a geographic atrophy (GA) lesion in the retina is generated via the deep learning system using the image input. The predicted growth output is associated with at least one future point in time after the first point in time.
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A plurality of instances of an assay may be performed to obtain a plurality of concentration data points. Next, a significant change point that corresponds to a location in the plurality of concentration data points at which one or more statistical characteristics of the plurality of concentration data points change by more than a threshold value may be identified. The significant change point may be correlated with one or more assay parameters associated with the assay by identifying an instance of performing the assay that corresponds to the location of the significant change point in the plurality of concentration data points. Based on the correlation, the cause for the change in the one or more statistical characteristics of the plurality of concentration data points at the identified significant change point may be determined.
The present disclosure relates to solid pharmaceutical compositions comprising a polypeptide as active agent and comprising mannitol. In some embodiments, the polypeptide active agent has been co-spray-dried with mannitol. In some cases, additional mannitol can be added after spray-drying. In some embodiments, the compositions comprise a compressed core comprising the co-spray-dried polypeptide active agent and mannitol. A variety of polypeptide active agents can be included in the compositions, as well as a variety of further excipients. In some cases, the compositions further comprise a coating, such as a seal coating and/or an enteric coating, such as a pH dependent enteric coating. In some embodiments, they can be orally administered. For example, the compositions can be in the form of tablets, pellets, capsules, or pills or the like, intended for oral administration. The disclosure also relates to methods of making and using the compositions, and kits comprising the compositions.
A computer-based method and system for predicting future geographic atrophy (GA) lesion growth. An optical coherence tomography (OCT) volume for a retina of a subject associated with a first point in time is received by a process over a network. A segmentation model is used to generate a segmented volume corresponding to the OCT volume, the segmented volume comprising a plurality of 3D segments. For each 3D segment of the plurality of 3D segments, a map output is generated. A set of biomarker values is computed for a corresponding set of biomarker features using the map output. A prediction system is used to generate a prediction output that predicts a progression of a GA lesion in the retina with respect to a future point in time after the first point in time using at least one of the set of biomarker values or the map output.
The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Provided herein, inter alia, are methods and compositions for engineering T cells. The methods include culturing a T cell with insulin during engineering of the T cell. The methods provided herein are contemplated to increase cell viability, expansion and gene editing efficiency, thereby allowing an increase in the total number of engineered T cells.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
19.
MACHINE LEARNING HISTOLOGICAL ANALYSIS FOR IDENTIFICATION OF MOLECULAR FEATURES
A method may include determining, within an image of a biological sample, a first plurality of tiles having a first tile size and a second plurality of tiles having a second tile size. A feature extraction model may be applied to extract features from the different size tiles. Concatenated feature sets, each of which including a first feature of a first tile from the first plurality of tiles, a second feature of a second tile from the second plurality of tiles, and a third feature of a third tile from the second plurality of tiles, may be formed. Molecular features present in the biological sample may be determined based on an attention-weighted position embedding of the concatenated feature sets and a joint representation of features across clusters of spatially proximate tiles in the image. Related systems and computer program products are also provided.
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
G06V 10/42 - Global feature extraction by analysis of the whole pattern, e.g. using frequency domain transformations or autocorrelation
G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
G06V 20/70 - Labelling scene content, e.g. deriving syntactic or semantic representations
An apparatus includes an instrument body and a flexible cannula extending distally from the instrument body that is sized and configured to advance between a sclera and a choroid of a patient's eye. The apparatus also includes a needle that is configured to translate relative to the cannula between a proximal position and a distal position. The apparatus further includes a rotary knob (422) configured to rotate relative to the instrument body about a rotational axis and thereby drive translation of the needle between the proximal and distal positions. The apparatus also includes a deflectable member (460) fixed against rotation relative to one of the instrument body or the rotary knob. The deflectable member is configured to frictionally engage the other of the instrument body or the rotary knob to prevent rotation of the rotary knob about the rotational axis absent application of a predetermined threshold rotational force to the rotary knob.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
The present invention relates to prognostic and therapeutic methods for the treatment of cancer (e.g., lung cancer, e.g., non-small cell lung cancer (NSCLC)) using expression levels of tumor-associated macrophage (TAM) and regulatory T cell (Treg) genes. In particular, the invention provides methods for patient selection and treatment.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
23.
METHODS OF TREATING LOCALLY ADVANCED OR METASTATIC BREAST CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
The invention provides methods and compositions for treating locally advanced or metastatic breast cancer and for enhancing immune function in an individual having locally advanced or metastatic breast cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07C 271/02 - Carbamic acidsSalts of carbamic acids
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
24.
METHOD AND APPARATUS FOR SUPRACHOROIDAL ADMINISTRATION OF THERAPEUTIC AGENT
An apparatus for delivering therapeutic agent to an eye comprises a body, a cannula, a hollow needle, and an actuation assembly. The cannula extends distally from the body and is sized and configured to be insertable between a choroid and a sclera of a patient's eye. The actuation assembly is operable to actuate the needle relative to the cannula to thereby drive a distal portion of the needle along an exit axis that is obliquely oriented relative to the longitudinal axis of the cannula. The cannula may be inserted through a sclerotomy incision to position a distal end of the cannula at a posterior region of the eye, between the choroid and sclera. The needle may be advanced through the choroid to deliver the therapeutic agent adjacent to the potential space between the neurosensory retina and the retinal pigment epithelium layer, adjacent to the area of geographic atrophy.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
The present disclosure provides, inter alia, methods of treating a locally advanced, recurrent, or metastatic solid tumor malignancy in a subject in need thereof by administering an anti-CCR8 antibody to the subject, and related therapeutic uses.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Methods and systems for foveal avascular zone (FAZ) segmentation of a retina. A three dimensional optical coherence tomography angiography (OCTA) volume of a retina of a subject is received. The OCTA volume comprising a plurality of layers. A slab input for a model system is formed using the OCTA volume. The model system comprising a deep learning model. A set of mask images is generated, via the model system, based on the slab input. The set of mask images includes an area mask image that accurately and reliably identifies an area of a foveal avascular zone captured by the OCT volume.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The present disclosure relates to methods for generating a plurality of compatible structures for a peptide-protein complex that can be used, for example, to identify surface fingerprint and interface features of the peptide-protein complex. The methods can comprise inputting peptide sequence data and protein sequence data into a trained machine learning model to determine: (i) predicted pairwise distance data for peptide amino acid residues and protein amino acid residue in the peptide-protein complex; and (ii) predicted dihedral angle data for peptide amino acid residues in the peptide-protein complex; identifying an initial structure for the peptide-protein complex based on the predicted pairwise distance and dihedral angle data; and generating the plurality of compatible structures for the peptide-protein complex based on the initial structure, the predicted pairwise distance data, and the predicted dihedral angle data.
C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
29.
SAMPLE PROCESSING AGNOSTIC IMAGE REPRESENTATION LEARNING FOR DIGITAL PATHOLOGY
Described herein are systems, methods, and programming for analyzing and classifying digital pathology images agnostic to sample processing techniques used to prepare the digital pathology images. In some embodiments, image data including a first image set and a second image set may be obtained. The first and second image sets may be processed using a first and second slide preparation machine, respectively. A first augmented view set and a second augmented view set may be generated based on augmentations applied to the first and second image sets. For each image, a first vision transformer to may be trained to: generate a first representation of an augmented view of the first augmented view set, and enhance a similarity between the first representation and a second representation of an augmented view of the second augmented view set. The second representation may be generated via a second vision transformer.
G06V 10/74 - Image or video pattern matchingProximity measures in feature spaces
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61P 13/08 - Drugs for disorders of the urinary system of the prostate
A61P 35/04 - Antineoplastic agents specific for metastasis
C30B 7/00 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
Disclosed, inter alia, are methods of preparing a phthalazinone Compound 1, which is useful for degradation of androgen receptor (AR). Also disclosed are methods of preparing intermediate compounds useful in the preparation of Compound 1. (Compound 1).
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present disclosure relates to peptides that bind to LRRC15. In some cases, the peptides are disulfide-constrained peptides (DCP). In some cases, the peptides bind to murine LRRC15 (muLRRC15).
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
33.
SOLID FORM OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3- FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9- TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL TARTRATE
The present invention relates to a crystalline form of giredestrant tartrate having an improved particle size distribution, as well as to processes for its preparation, pharmaceutical compositions comprising it, and its use as a medicament.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
34.
BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS
Provided herein are biomarkers, and combinations of biomarkers, for predicting sensitivity to cancer treatments, wherein the presence of a mutation to AKT correlates with sensitivity of the cancer to AKT inhibitors, such as (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
The present disclosure relates to methods, cells and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interests, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have modulated lactogenic activity. The present disclosure also relates to methods and compositions for modulating pyruvate kinase muscle (PKM) expression (e.g., PKM-1 expression) in a mammalian cell to thereby reduce or eliminate the lactogenic activity of the cell, as well compositions comprising a cell having reduced or eliminated lactogenic activity and methods of using the same.
A method that is implemented by one or more computer devices and that includes receiving an image associated with a portion of anatomy of a subject. Boundary points are extracted for an initial boundary associated with a corresponding region of pixels in the image. The boundary points are evaluated according to a sequential order to select anchor points. The evaluating includes determining that a current boundary point being evaluated is a next anchor point when at least one perpendicular distance computed for a portion of the initial boundary located between a previous anchor point and the current boundary point with respect to a line extending between the previous anchor point and the current boundary point is greater than a selected threshold. An anchor point image is generated for display in a graphical user interface on a display device. The anchor point image includes anchor indicators that represent the anchor points.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
37.
DEEP LEARNING ENABLED SEGMENTATION OF MEDICAL IMAGES WITH MISSING MODALITIES
A first training sample having a first modality configuration and a second training sample having a second modality configuration are generated based on a training image. The first and second modality configuration having a different combination of modalities. A segmentation model is trained based on the first and second training sample to perform a first task of operating on the first modality configuration and a second task of operating on the second modality configuration. The segmentation model is trained to generate an output segmentation map based on outputs from a first subset of parameters in the segmentation model and a second subset of parameters in the segmentation model. The training of the segmentation model includes adjust the parameters of the segmentation model to determine, for each of the first and second task, a different combination of weights for combining the outputs of the first and second subset of parameters.
A method may include applying a cell classification model to identify, based at least on an image of a biological sample, one or more cell types present in the biological sample. The cell classification model may be trained to differentiate between a plurality of cell types including a first cell type whose likelihood of being a macrophage satisfies a threshold and a second cell type whose likelihood of being the macrophage fails to satisfy the threshold. A composition profile for the biological sample may be generated based on the one or more cell types identified in the biological sample. At least one of a disease diagnosis, a disease progress, a disease burden, and a treatment response for a patient associated with the biological sample may be determined based on the composition profile of the biological sample. Related systems and computer program products are also provided.
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The present invention relates to the field of protein purification. In particular, the invention concerns methods for increasing the filtration capacity of virus filters, by combined use of endotoxin removal and cation-exchange media in the prefiltration process.
The invention provides a compound represented by represented by the following strutural formula:
The invention provides a compound represented by represented by the following strutural formula:
or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Some embodiments of the invention provide compounds having the general formula I:
Some embodiments of the invention provide compounds having the general formula I:
Some embodiments of the invention provide compounds having the general formula I:
wherein R1, R2, R3a and R3b are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.
The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positiv metastatic breast cancer in patients who did not receive prior chemotherapy or biologic therapy with a HER2 antibody binding essentially to epitope 2C4, a HER2 antibody binding essentially to epitope 4D5, and a taxane. The invention further comprises extending survival of such patients by the combination therapy of the present invention. In a preferred embodiment, the treatment involves administration of trastuzumab, pertuzumab and docetaxel.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
The invention provides a compound represented by represented by the following structural formula:
The invention provides a compound represented by represented by the following structural formula:
The invention provides a compound represented by represented by the following structural formula:
or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
The invention provides a compound represented by represented by the following strutural formula:
or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.
The invention provides a compound represented by represented by the following strutural formula:
or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
An apparatus and method for direct drug infusion from a vial to a patient are provided. A movable hanger label is provided to adhere to and support the vial to facilitate direct infusion of a drug, such as one or more pharmaceuticals, biopharmaceuticals, and/or biologics, from the vial to the patient. Additionally, a process is provided in which the drug, contained in the vial with the movable hanger label, may be directly infused through a primed infusion line with a rapid infusion rate. A saline flush is incorporated at the end of the administration to flush the infusion line, resulting in a reduced amount of the drug remaining in the line.
The present disclosure provides methods for combinatorial indexing of nucleic acids of single cells or nuclei. In particular, the methods of the present disclosure result in the incorporation of at least two index sequences within the nucleic acids of single cells or nuclei. The present disclosure further provides methods for generating and sequencing libraries of such indexed nucleic acids.
A method for developing a therapeutic such as, for example, a peptide vaccine. A machine learning model is trained using a metric learning algorithm, training peptide sequence data, and training allele presentation data corresponding to the training peptide sequence data. Peptide sequence data identifying peptide sequences that correspond to peptides is received. A peptide sequence vector is generated, via a machine learning model, for each peptide sequence using the peptide sequence data to form a plurality of peptide sequence vectors. An output is generated using the plurality of peptide sequence vectors. The output provides an indication of similarity between peptide sequences of the plurality of peptide sequences. A group of candidate peptides is selected from the plurality of peptides for development of the therapeutic based on the output such that the group of candidate peptides includes at least two dissimilar candidate peptides.
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
50.
METHODS FOR TREATMENT OF PANCREATIC CANCER WITH ANTI-PD-L1 AB, ANTI-TIGIT AB, GEMCITABINE AND NAB-PLACLITAXEL
The present invention relates to the treatment of PD-L1 -positive pancreatic cancer, e.g., PD-L1-positive pancreatic ductal adenocarcinoma (PDAC), e.g., PD-L1 -positive metastatic PDAC. More specifically, the invention pertains to the treatment of patients having a PD-L1 -positive pancreatic cancer by administering an anti-TIGIT antagonist antibody and an anti-PD-L1 antagonist antibody, e.g., by administering an anti-TIGIT antagonist antibody and an anti-PD-L1 antagonist antibody in combination with one or more chemotherapeutic agents.
A61K 31/00 - Medicinal preparations containing organic active ingredients
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies and lenalidomide.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure provides methods for treating childhood-onset idiopathic nephrotic syndrome (INS), or reducing risk and/or frequency of relapse from childhood-onset INS, in an individual that is greater than or equal to 2 years of age and less than or equal to 25 years of age. In some embodiments, the methods comprise administering to the individual an effective amount of obinutuzumab.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
53.
DIAGNOSTIC AND THERAPEUTIC METHODS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA)
The present invention provides prognostic, predictive, and therapeutic methods for the treatment of rheumatoid arthritis (RA). The invention is based, at least in part, on the discovery that the expression level of one or more biomarkers described herein in a sample (e.g., a synovial tissue sample, a synovial fluid sample, or a combination thereof) from an individual having RA can be used in methods of determining whether an individual having RA is likely to exhibit disease progression, identifying an individual having RA who is likely to respond to a treatment including a disease modifying anti-rheumatic drug (DMARD), predicting responsiveness of an individual having RA to a treatment including a DMARD, selecting a therapy for an individual having RA, and treating an individual having RA, as well as related kits.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
54.
THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER
The invention provides methods and compositions for treating bladder cancer (e.g., urothelial carcinoma (UC), including locally advanced or metastatic UC) in a subject, for example, by administering a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) to the patient. Also provided are compositions (e.g., a PD-1 axis binding antagonist (e.g., atezolizumab) and/or a platinum-based chemotherapy (e.g., cisplatin or carboplatin and gemcitabine), pharmaceutical compositions thereof, kits thereof, and articles of manufacture thereof) for use in treating bladder cancer (e.g., UC, including locally advanced or metastatic UC) in a patient. Also provided are assays and methods for determining the presence and/or expression level of PD-L1 in a sample obtained from a patient and for labeling PD-L1 in a sample obtained from a patient.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 13/10 - Drugs for disorders of the urinary system of the bladder
A method may include training a machine learning model to determine a first pharmacokinetic parameter and a second pharmacokinetic parameter for a molecule. The machine learning model may be trained by at least determining, based at least on an input including one or more pharmacokinetic models associated with the molecule, a first value of the first pharmacokinetic parameter, determining, based at least on the input, a second value of the first pharmacokinetic parameter, and determining, based at least on the first value and the second value of the first pharmacokinetic parameter, a third value of the second pharmacokinetic parameter. The method may also include applying the trained machine learning model to determine, based at least on a sparsely sampled pharmacokinetic model associated with the molecule, the first pharmacokinetic parameter and/or the second pharmacokinetic parameter. Related methods and articles of manufacture are also disclosed.
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
A method may include extracting a plurality of features for each cell depicted in an image. A biomarker identification model may be applied to determine, based on the features associated with each cell, whether the cell is associated with various biomarkers. A set of probabilities for each cell in the population of cells may be determined based on an output of the biomarker identification model. The set of probabilities may include, for each biomarker, a probability of a corresponding cell being associated with the biomarker. One or more subsets of cells, each of which corresponding to a different cellular phenotype, may be identified based on the set of probabilities associated with each cell. A feature set associated with each subset of cells may be identified as being indicative of a probability of a cell being associated with a corresponding phenotype. Related systems and computer program products are also provided.
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G06V 10/40 - Extraction of image or video features
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
57.
ANTI-C-C MOTIF CHEMOKINE RECEPTOR 8 (CCR8) ANTIBODIES AND METHODS OF USE
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder. More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure relates to the simultaneous imaging of nucleic acids and proteins in a sample. In particular, the present disclosure provides compositions, methods, systems and kits for imaging at least one target protein and at least one target nucleic acid in a single sample.
Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Hbb]pyrazine compound of formula (I), or a stereoisomer thereof: Formula (I), or a pharmaceutically acceptable salt thereof; and compounds prepared by these processes.
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
64.
DATA-INDEPENDENT ACQUISITION (DIA) FOR MASS SPECTROMETRIC ANALYSIS OF MHC PEPTIDES
e.g.e.g., a patient sample). In some instances, for example, the methods can comprise: predicting, using one or more machine-learning models, an MHC allele-specific mass spectral library for the sample; performing a mass spectrometric analysis of peptides extracted from the sample using data-independent acquisition (DIA) to generate mass spectral data for the peptides; and performing a spectral library search using the mass spectral data for the peptides and the predicted MHC allele-specific mass spectral library for the sample to identify at least one MHC peptide present in the sample.
G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
65.
MACHINE LEARNING ENABLED PREDICTION OF MOLECULAR STRUCTURES AND PROPERTIES
A method may include receiving a molecular structure file specifying an initial three-dimensional structure of a molecule. A representation of the molecule may be determined based on the molecular structure file. For example, the representation of the molecule may include a plurality of coarse-grained nodes, each corresponding to a structural body of two or more atoms (e.g., heavy atoms) forming an amino acid residue in the molecule. Alternatively, the representation of the molecule may include, for each residue in the molecule, a plurality of frames specifying a geometric state of the backbone of the residue and one or more torsion angles in the sidechain of the residue. A design computation model may be applied to determine a three-dimensional structure of the molecule by at least modifying the representation of the molecule. The three-dimensional structure may be associated with a desirable property and/or be configured for a downstream task.
e.g.e.g.e.g., tuberculosis, leprosy, nontuberculous mycobacterial infections, or a combination thereof). Pharmaceutical compositions comprising said compounds are also provided.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G06F 16/28 - Databases characterised by their database models, e.g. relational or object models
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
68.
CROSS-MODALITY PIXEL ALIGNMENT AND CELL-TO-CELL REGISTRATION ACROSS VARIOUS IMAGING MODALITIES
A method implemented by one or more computer devices includes receiving a plurality of images of a set of tissue cells, the plurality of images comprising a first image including a first visualization modality and a second image including a second visualization modality. The method includes identifying a first tissue cell of the set of tissue cells in the first image and the first tissue cell in the second image, and performing a cell-to-cell registration process based on the first tissue cell identified in the first image and the first tissue cell identified in the second image. The cell-to-cell registration process includes matching of the first tissue cell identified in the first image to the first tissue cell identified in the second image. The method includes classifying the first tissue cell into a phenotype based on the cell-to-cell registration process, the phenotype partially indicative of a disease pathology.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
69.
SPACETIME ATTENTION FOR CLINICAL OUTCOME PREDICTION
A disease prognosis model to may be trained to determine the clinical outcome of a disease based on longitudinal data including a health record for each timepoint in a sequence of timepoints. The disease prognosis model may include a recurrent neural network trained to extract, from each health record, a feature set representative of local dependencies present within the health record. The disease prognosis model may include a spacetime attention trained to determine an importance of each feature in the feature set at each timepoint in the sequence of timepoints. The disease prognosis model may include a feedforward neural network trained to determine, based on the importance of each feature in the feature set at each time point in the sequence of timepoints, the clinical outcome of the disease. The trained disease prognosis model may be applied to determine the clinical outcome of the disease for one or more patients.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
70.
PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES
The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
In one embodiment, a method includes accessing a biomolecule representation of a first biomolecule and processing the biomolecule representation by a machine-learning model trained using sequencing time-series data. The sequencing time-series data was obtained from directed evolution of a population of biomolecules over multiple enrichment rounds where the population of biomolecules in each enrichment round was a unique set of biomolecules with respect to each other enrichment round. The sequencing time-series data for each enrichment round comprises a biomolecule frequency of each biomolecule of the population of biomolecules in the respective enrichment round. The training comprises learning inferred fitness scores of the population of biomolecules for each enrichment round by predicting biomolecule frequencies of the population of biomolecules in the respective enrichment round given biomolecule frequencies of the population of biomolecules in prior enrichment rounds. The method further includes outputting an inferred fitness score for the first biomolecule.
The present invention relates to methods of increasing hemoglobin in an individual suffering from severe hemophilia A by prophylactic administration of emicizumab. Pharmaceutical compositions comprising emicizumab are also provided.
The present disclosure provides methods for treating an individual with a urothelial carcinoma with an individualized cancer vaccine and a PD-1 axis antagonist.
A method may include determining, by at least one data processor and based on a set of cellular kinetics parameters corresponding to a plurality of T cell phenotypes and trafficking rates of the plurality of T cell phenotypes between a peripheral tissue and lymph node compartment (i.e., healthy tissue compartment), a blood compartment, a tumor draining lymph node compartment, and a tumor compartment, a distribution of the plurality of T cell phenotypes over time. The plurality of T cell phenotypes may include a stem-like memory T cell, a central memory T cell, an effector memory T cell, an effector T cell, and an endogenous T cell. Related methods and articles of manufacture are also disclosed.
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
76.
MOLECULE DESIGN WITH MULTI-OBJECTIVE OPTIMIZATION OF PARTIALLY ORDERED, MIXED-VARIABLE MOLECULAR PROPERTIES
One or more property computational models may be applied to determine a first probability of a molecule design exhibiting a first property and a second probability of the molecule design exhibiting a second property. A plurality of samples in which each sample includes a first value of the first property and a second value of the second property exhibited by the molecule design may be determined based on the output of the property computational models. A set of samples in which the first value of the first property satisfies a criterion may be identified. A utility metric corresponding to an expected improvement of the first property and the second property of the molecule design over that of baseline molecule designs may be determined based on the set of samples. One or more molecule designs may be identified as candidates for synthesis based on the corresponding utility metrics.
Various lactam compound that binds Cbl-B, many of which are selective for Cbl-B over C-Cbl, and methods of making and using the same. Representative lactam compounds include molecules falling within the following formulae:
Various lactam compound that binds Cbl-B, many of which are selective for Cbl-B over C-Cbl, and methods of making and using the same. Representative lactam compounds include molecules falling within the following formulae:
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
We provide a method of optimizing sialic acid content for a recombinant polypeptide. The method comprises culturing a cell-line engineered to express the recombinant polypeptide under conditions promoting production of the recombinant polypeptide; monitoring cell viability of the cultured cell-line on at least one of days 7, 8, 9, 10, 11 or 12 of the culturing. If the cell viability is at or below a threshold level, the method also comprises stopping the culture and isolating the recombinant polypeptide after a first predetermined additional time. If the cell viability is above the threshold level, the method also comprises stopping the culture and isolating the recombinant polypeptide after a second predetermined additional time. The second predetermined additional time is at least about 12 hours longer than the first predetermined time.
The present disclosure relates to a novel platform for targeted degradation of target protein. The disclosure relates to degradation of target proteins comprising peptide expression tags of small size, such as 25 amino acids or less, by fusion polypeptides comprising an E3 ubiquitin ligase and a binding polypeptide that recognizes the peptide expression tag of the target protein. In some embodiments, the E3 ubiquitin ligase comprises the catalytic domain of a bacterial E3 ubiquitin ligase, and in some cases does not comprise the native substrate binding domain of the E3 ubiquitin ligase.
Described herein are techniques for identifying regions of substantia nigra reticulata (SNR) and regions of substantia nigra compact dorsal (SNCD) in histology images and quantifying a number of dopaminergic neural cells within the images. In some embodiments, an image of a section of a brain may be input into a first machine learning model to obtain a first segmentation map comprising pixel-wise labels indicative of whether a corresponding pixel in the image depicts a region of SNR or SNCD. In some embodiments, the image (and, optionally, the first segmentation map) may also be input to a second machine learning model trained to generate a second segmentation map comprising pixel-wise labels indicating whether a corresponding pixel of the image depicts a dopaminergic neural cell or neural background tissue. The number of cells within the image may be determined based on the second segmentation map.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G06V 10/24 - Aligning, centring, orientation detection or correction of the image
G06V 10/32 - Normalisation of the pattern dimensions
G06V 10/40 - Extraction of image or video features
G06V 10/77 - Processing image or video features in feature spacesArrangements for image or video recognition or understanding using pattern recognition or machine learning using data integration or data reduction, e.g. principal component analysis [PCA] or independent component analysis [ICA] or self-organising maps [SOM]Blind source separation
G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G06V 20/70 - Labelling scene content, e.g. deriving syntactic or semantic representations
81.
DETERMINING A PATIENT’S RESPONSE TO A TREATMENT IN MULTIPLE MYELOMA
The present disclosure relates to a computer-implemented method of a computer-implemented method of determining a patient's response to a treatment in multiple myeloma. The method comprises:
providing results of a series of predefined consecutive tests on the patient,
determining a response at time t as a function of a test result of the time t and a subsequent test result of a time t+1.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
The invention relates to compositions (e.g., pharmaceutical compositions) that include, for example, IL-22 Fc fusion proteins, methods of making the same, and methods of using the same, e.g., for the treatment of diseases (e.g., IBD).
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
83.
QUANTIFYING AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA) IN ALZHEIMER'S PATIENTS
Methods for quantifying amyloid related imaging abnormalities (ARIA) in a brain of a patient are provided. The method includes accessing a set of one or more brain-scan images associated with the patient, and inputting the set of one or more brain-scan images into one or more machine-learning models. The one or more machine-learning models are trained to generate a segmentation map based on the set of one or more brain-scan images, the segmentation map including a plurality of pixel-wise class labels corresponding to a plurality of pixels in the segmentation map. The one or more machine-learning models are further trained to generate a classification score based on the segmentation map. The method thus includes detecting ARIA in the brain of the patient based on the classification score.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G01R 33/50 - NMR imaging systems based on the determination of relaxation times
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
84.
COMPOSITION AND METHODS FOR ADENO-ASSOCIATED VIRUS PRODUCING STABLE HUMAN EMBRYONIC KIDNEY-293 CELL LINES
The presently disclosed subject matter relates to compositions and methods for the generation of stable human embryonic kidney-293 (HEK-293) cell lines for adeno-associated virus (AAV) production.
The present disclosure involves preparing a cryostat tissue section for use with electron microscopy and other high resolution imaging techniques. A tissue sample is soaked in a solution having a predefined concentration of freeze protectant that prevents creation of freeze damage artifacts in the tissue sample that are greater than 10 nanometers in at least one dimension. The tissue sample is frozen in order to perform a cryostat sectioning. The cryostat sectioning is performed on the tissue sample to produce a cryostat tissue section. The cryostat tissue section is mounted onto a slide, and the cryostat tissue section is covered on the slide with the solution having the predefined concentration of freeze protectant.
Methods for segmenting and detecting amyloid related imaging abnormalities (ARIA) in a brain of a patient are provided. The method includes accessing a set of one or more brain-scan images associated with the patient, and inputting the set of one or more brain-scan images into one or more machine-learning models trained to generate a segmentation map based on the set of one or more brain-scan images. The segmentation map includes a plurality of pixel-wise class labels corresponding to a plurality of pixels in the segmentation map, in which at least one of the plurality of pixel-wise class labels includes an indication of ARIA in the brain of the patient. The method further includes outputting a quantification of ARIA in the brain of the patient based at least in part on the segmentation map.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G06V 10/26 - Segmentation of patterns in the image fieldCutting or merging of image elements to establish the pattern region, e.g. clustering-based techniquesDetection of occlusion
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
87.
COMBINATIONS OF IL15/IL15R ALPHA HETERODIMERIC FC-FUSION PROTEINS AND FCRH5XCD3 BISPECIFIC ANTIBODIES FOR THE TREATMENT OF BLOOD CANCERS
The disclosure provides methods of treating a blood cancer, such as multiple myeloma, by administering a combination of a heterodimeric protein comprising a first monomer comprising an IL15 protein-Fc domain fusion and a second monomer comprising an IL15Rα protein-Fc domain fusion, such as XmAb24306, and a FcRH5xCD3 bispecific antibody, such as cevostamab.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
88.
MACHINE LEARNING ENABLED ANALYSIS OF MEDICAL IMAGING DATA FOR ASSESSMENT OF DISEASE PROGRESSION AND TREATMENT RESPONSE
A method may include determining a first tumor mask identifying a first set of lesions present in a first positron emission tomography and computed tomography (PET/CT) scan from a first timepoint. A second tumor mask identifying a second set of lesions present in a second PET/CT scan from a second timepoint may be determined. A first matching lesion in the second tumor mask that corresponds to a first target lesion selected from the first set of lesions in the first tumor mask, the first matching lesion being identified based at least on an overlap between a first plurality of pixel coordinates of the first target lesion in the first tumor mask and a second plurality of aligned pixel coordinates of the first matching lesion in the second tumor mask aligned with the first tumor mask may be identified based at least on the first tumor mask and the second tumor mask. A change in metabolic level between the first timepoint and the second timepoint may be determined based on at least a metabolic level of each of the first target lesion in the first PET/CT scan and the first matching lesion in the second PET/CT scan. A response to a treatment for a disease may be determined, based at least on the change in metabolic level between the first timepoint and the second timepoint.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The present disclosure involves generating a view of a tissue section that combines a scanning electron microscope image with a mass spectrometry image of the tissue section. Specifically, a scanning electron microscope image of at least a first portion of an ultramicrotome tissue section of a tissue sample is generated using a scanning electron microscope. Also, a mass spectrometry image of at least a second portion of the ultramicrotome tissue section is generated using a mass spectrometry imaging platform, where the mass spectrometry image depicts an antibody labeling of at least one element. The scanning electron microscope image is registered with the mass spectrometry image.
G01N 23/2208 - Combination of two or more measurements, at least one measurement being that of secondary emission, e.g. combination of secondary electron [SE] measurement and back-scattered electron [BSE] measurement all measurements being of secondary emission, e.g. combination of SE measurement and characteristic X-ray measurement
G01N 23/2251 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by measuring secondary emission from the material using electron or ion microprobes using incident electron beams, e.g. scanning electron microscopy [SEM]
G01N 23/2258 - Measuring secondary ion emission, e.g. secondary ion mass spectrometry [SIMS]
The disclosure relates to methods of producing a glycoprotein with reduced a-Gal content by reducing pH from 7.20 to 6.90, by increasing GlcNAc or zinc concentration and/or by reducing uridine or manganese concentration. Also provided are glycoproteins obtained or obtainable by said methods.
The present disclosure relates to improved methods for imaging target nucleic acids by in situ sequencing. In particular, the present disclosure provides nucleic acid constructs (and compositions thereof), methods, systems, and kits for imaging at least one target nucleic acid in a single sample using in situ sequencing.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
The presently disclosed subject matter relates to compositions and methods for the generation of stable human embryonic kidney-293 (HEK-293) cell lines for adeno- associated virus (AAV) production.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Educational services, namely, providing presentations in the field of oncology products and diseases; training services in the field of oncology products and diseases Medical services in the field of oncology products and diseases
Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure:
Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure:
Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure:
or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
C07D 267/08 - Seven-membered rings having the hetero atoms in positions 1 and 4
A method includes identifying, based at least on an identification information associated with an image set depicting one or more slices of tissue from at least one block of a tissue sample, one or more of a duplicate image, a replicate image, and a multiple image present within the image set. The one or more of the duplicate image, the replicate image, and the multiple image may be further identified based on a metric indicative of a minimal difference achieved between each pair of images in the image set while adjusting an alignment therebetween. The identification information associated with the image set may be updated to indicate the one or more of the duplicate image, the replicate image, and the multiple image identified as present within the image set. Related systems and computer program products are also disclosed.
This invention relates to a method for modulation of disulfide structural isoform distribution in a recombinant protein. The invention also relates to a method of stabilizing disulfide structural isoform distribution by preventing disulfide bond rearrangement in a recombinant protein, methods for the production of a recombinant protein with modulated disulfide isoforms, and a method for altering disulphide structural isoform distribution by enhancing disulfide bond rearrangement in a recombinant protein. The invention also relates to a use of a reducing agent for modulation of disulfide structural isoform distribution by enhancing disulfide bond rearrangement in a recombinant protein, and to a use of an oxidising agent for stabilizing disulfide structural isoform distribution by preventing disulfide bond rearrangement in a recombinant protein.
Herein is provided a method of determining a high-resolution structure of a molecule comprising determining a high-resolution structure of a complex comprising the molecule and an antibody or antigen-binding fragment thereof or the antibody scaffold that binds to the molecule, wherein the antibody or antigen-binding fragment comprises one or more engineered disulfide bonds that increase conformational rigidity of the antibody or antigen-binding fragment thereof or the antibody scaffold, and thereby determining the high-resolution structure of the molecule using cryo-EM.
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
100.
PEAK DECONVOLUTION FOR CHROMATOGRAPHIC TIME-SERIES COMPOSITE SIGNALS
The present disclosure is directed to systems and methods for accessing and analyzing a chromatographic time-series composite signals comprising multiple signal distributions and deconvoluting the signal distributions to correlate such deconvoluted signals with chemical constituents in a variety of sample types, e.g., biopharmaceutical purification process samples.
